In short
Clinical trials investigating Varenicline are studying its role in smoking cessation. The trial data here look at adults who smoke at least 10 cigarettes per day and compare Varenicline with placebo and electronic cigarettes. These studies focus on efficacy, especially continuous smoking abstinence, in a Phase 3 setting.
Key points
- Clinical trials investigating Varenicline in the provided data focus on smoking cessation. The main study is a Phase 3 interventional trial in adults who smoked at least 10 cigarettes per day in the past year. It compares Varenicline with placebo and with electronic cigarettes as a reference treatment. The main result being measured is continuous smoking abstinence during the last 4 weeks of a 3-month treatment period. The trial listed here is suspended, so it is not currently continuing as planned.
Trial overview
The trial data provided here describe one interventional study, which means researchers assigned study treatments to participants rather than only observing them. The study looked at smoking cessation, which means helping people stop smoking.
The study title was Use of electronic cigarettes for smoking cessation, and it included Varenicline as a reference treatment for comparison. The brief summary says the study aimed to assess the efficacy of electronic cigarettes with nicotine compared with electronic cigarettes without nicotine and with the licensed smoking cessation medication Varenicline.
Who was studied
The trial targeted smokers smoking at least 10 cigarettes/day in the past year. This means the study focused on people with regular smoking habits, not occasional smokers.
The provided data do not list other eligibility details, so the main known target group is this smoking population.
What was tested
The study compared three approaches: electronic cigarettes containing nicotine, electronic cigarettes without nicotine, and Varenicline as the reference medication. A placebo version of CHAMPIX was also listed, which means an inactive comparison treatment was used in the trial design.
Because the trial focused on smoking cessation, the comparison was meant to show which approach helped people stay smoke-free more effectively.
Study phase and status
This was a Phase 3 trial. Phase 3 studies usually test a treatment in a larger group of people to better understand how well it works in real study conditions.
The study status was Suspended. In simple terms, this means the trial was stopped for now and was not continuing as planned in the source data.
Main endpoint
The main endpoint was the continuous smoking abstinence rate during the last 4 weeks of a 3-month treatment period. An endpoint is the main result researchers measure to judge whether a study treatment is working.
In patient terms, this endpoint asks whether people stayed smoke-free without interruption during the last month of treatment.
What the results aim to show
The study was designed to compare Varenicline with other smoking cessation approaches, especially electronic cigarettes with and without nicotine. The goal was to evaluate whether these approaches could help people stop smoking, with the main focus on sustained abstinence.
The enrolled number was planned at 650 participants, showing that this was meant to be a fairly large smoking cessation study. No numerical results were provided in the source data, so this article only summarizes the study design and goals.